Life is a beautiful gift and health is what allows us to enjoy it. That is why we are deeply committed to helping patients. No matter how complex or rare the disease may be, we don‘t give up. Our ~17,800 Healthcare employees wake up every day motivated by our purpose: To help create, improve and prolong lives – as one for patients. We are the Healthcare business of Merck, and the only pharmaceutical company that is developing solutions along the whole “circle of life”. For over 350 years, patients have always been at the heart of everything we do. Our pioneering work in cancer treatment is focused on discovering, developing and delivering science-driven breakthrough therapies that turn cancer patients into cancer survivors. Our tireless passion for R&D as well as a creative and focused approach help accelerate innovation in oncology and immuno-oncology. To realize our ambition, we’ve created a balanced portfolio. Our core business helps provide a strong foundation, fund innovation and mitigate risks. Our specialty portfolio enables us to be on the frontlines of change and truly become a specialty innovator. We have a proud history of advancing care in immunology for people living with chronic progressive diseases such as multiple sclerosis. For more than two decades we have maintained our commitment to delivering innovative solutions across treatment, devices, and support services. This dedication drives the research and development of our pipeline products and our efforts to address areas of unmet medical need. Today, we are a global market leader in the field of fertility treatments. Our therapeutic portfolio, devices and advanced fertility technologies have helped many couples achieve their dream of having a baby. Everyone should have the opportunity to become a parent. To date, more than 5 million babies have been brought into the world with the help of our leading fertility products. Imprint: merckgroup.com/imprint Not intended for US & CA visitors.

Women spend on average nine years in poor health, yet they remain underrepresented in clinical research and STEM education, and global birth rates have reached an all-time low. These challenges carry significant economic implications, including productivity losses, absenteeism, and rising healthcare costs. During the World Economic Forum in Davos, Leif E. Moll, President of Merck in Switzerland, joined Gudrun Sander, Prof. Dr. , Kendra Jones, and Silvia Candamil Neira in a panel discussion hosted by the WORLD WOMAN FOUNDATION to discuss these challenges and actions to be taken to improve women’s health. Key findings included the urgent need to invest in women's health to create prosperous economies, the importance of cross-sector collaboration, and the need for policies that ensure equitable access to healthcare and education. From a business perspective, it is essential to prioritize family-friendly policies and workplace well-being. This is also why we at Merck Group have introduced initiatives such as the Fertility Benefit and the Caregiver Leave Benefit, fostering an inclusive and caring culture. #HealthyWomenHealthyEconomies #WorldWomanDavos #WEF2026 #WEF

What is the future of AI in Europe? Emre Ozcan, PhD , Global Head of Digital Health and Imogen Marouillat , Head of Solution Delivery, took a moment at the #AIforHealth event in Paris to discuss the three things that need to go right to secure Europe’s position as a leader in AI in healthcare. What factors would you add? #HealthcareInnovation #DigitalHealth

FDA Accepts Pimicotinib New Drug Application Yesterday, the US Food and Drug Administration accepted our New Drug Application for pimicotinib for certain adult patients with symptomatic tenosynovial giant cell tumors (TGCT)—a rare tumor that can significantly impact quality of life. This brings us one step closer to potentially delivering a new systemic treatment option for patients in the US living with this challenging disease. Read more: https://lnkd.in/d6zkMATf #AsOneForPatients #TGCT #RareDisease

Today, following Priority Review, the China National Medical Products Administration (NMPA) has granted approval of pimicotinib for certain adult patients with symptomatic tenosynovial giant cell tumors (TGCT), a rare tumor that can significantly impact patients' quality of life. With the approval of pimicotinib, developed by our partner 和誉医药 Abbisko Therapeutics, healthcare professionals in China will soon have the opportunity to prescribe their patients an effective and well-tolerated systemic treatment option, offering a much-needed advance in how they manage this challenging condition. Read more: https://lnkd.in/ebe6ipeb #AsOneForPatients #TGCT #RareDisease

#MeetTheAdvocate : AllPaths Family Building! This organization, based in the United States, is committed to supporting individuals facing fertility and family-building challenges. Learn more about the group and its mission from Executive Director Kate Weldon LeBlanc. #FamilyBuilding #FertilitySupport #AsOneForPatients

Merck Turkey has been awarded the Diversity and Inclusion Management Award in the Value-Creating Practices category at the PERYÖN Türkiye İnsan Yönetimi Derneği People Management Awards. This recognition reflects our strong commitment to building an inclusive and supportive workplace culture through our EmpowerHer initiative and comprehensive HR practices. Our efforts include Special Moments Leave and Fertility Benefit, inclusive health insurance coverage, impactful leadership development programs, and initiatives that advance women’s empowerment in education, healthcare, and professional development. With the support of the Merck Family Foundation, our 25th Anniversary Scholarship Fund continues to provide long-term scholarship support to 25 female students affected by the earthquake — helping create equal opportunities and lasting social value. With strong representation of women across our workforce and leadership levels, we remain committed to promoting equal opportunities and investing in programs that foster inclusive leadership. This award further strengthens our motivation to accelerate our efforts toward a more inclusive future. #TeamMerck #PERYÖN #MerckTurkiye

How is AI reshaping healthcare delivery? We caught up with Emre Ozcan, PhD , Global Head of Digital Health and Imogen Marouillat , Head of Solution Delivery at the recent #AIforHealth in Paris. By connecting fragmented healthcare systems, automating repetitive tasks for professionals, and co-designing solutions with patients and clinicians, we are driving innovation with real impact. #AIinHealthcare #DigitalHealth #AsOneForPatients

Around the world, the burden of Type 2 Diabetes continues to rise. So across the Gulf, our colleagues chose action: to show type 2 diabetes the red card. This year, our teams from the UAE, Oman, Qatar, Kuwait, Bahrain and Yemen came together for the Gulf Diabetes Walk, a region-wide initiative championing early detection, healthier choices, and community awareness. What started as a simple walk became something larger: a powerful reminder that collective steps can drive meaningful change. We’re proud of our colleagues across the Gulf for bringing Merck’s purpose to life in such a tangible way. #WeAreMerck #DiabetesAwareness #ShowType2DiabetesTheRedCard #PublicHealth #AsOneForPatients #MerckGulf

How can Europeans realize the families they dream of? At the European Parliament , voices from across the policy, patient, and healthcare community recently gathered to address this question. Hosted by MEP Romana Jerković, the event brought together patient advocates like Maciej Śmiechowski of Fertility Europe , policy leaders, and healthcare experts including Marieta Jiménez , Senior Vice President Europe at Merck Healthcare. Together, they highlighted that declining fertility rates are not just statistics—they touch lives, economies, and the future of our societies. Therefore, our Fertility Manifesto outlines three urgent priorities for Europe: • Integrate fertility education into health and school curricula, closing the knowledge gap for young people. • Create family-friendly policies that support people’s choices—at work and in society. • Ensure timely diagnosis and fair access to innovative fertility care. As Marieta Jiménez reminded us, real progress “requires a collective effort of policymakers, healthcare providers, and the private sector…empowering individuals in making informed and free choices about family planning and reproductive health.” Read more here: https://lnkd.in/dJ923znx #ReproductiveHealth #FamilyFriendlyEurope #AsOneForPatients

Infertility affects 25M people in the EU – yet policy gaps still leave too many without access to care. At European Society of Human Reproduction and Embryology (ESHRE) this year, we tackled one of the most urgent issues of our time: the global fertility challenge. Our message was clear – to solve it, it requires bold, inclusive reforms that make family-building possible for everyone, regardless of income, age, or relationship status. Read the latest #BoldDirections article, that unpacks the key themes from #ESHRE and explores how policy change can bridge the fertility gap and open the door to care for all. https://lnkd.in/e7pjdd76 #AsOneForPatients #FertilityCare